Weekly Research Analysts’ Ratings Changes for ABIOMED (ABMD)

A number of firms have modified their ratings and price targets on shares of ABIOMED (NASDAQ: ABMD) recently:

  • 2/6/2018 – ABIOMED was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “In the fourth quarter, ABIOMED reported stellar performance, beating the Zacks Consensus Estimates for both revenue and earnings. The robust demand for the Impella product line continues to drive Abiomed’s top line. The company’s expanding product portfolio is likely to improve penetration into the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that Impella 2.5 and CP continue to add centers in the United States. The company successfully launched the Abiomed Impella Quality Program in 2017 to improve clinical outcomes. New achievements in the last quarter, are also encouraging. However, intense competition in the niche markets is likely to mar prospects over the long haul. Abiomed’s significant international presence exposes it to fluctuations in currency exchange rates. The company is likely to face increasing pricing pressure, thanks to growing competition in key markets.”
  • 2/4/2018 – ABIOMED had its “hold” rating reaffirmed by analysts at BTIG Research.
  • 2/2/2018 – ABIOMED had its price target raised by analysts at Leerink Swann to $300.00. They now have an “outperform” rating on the stock.
  • 2/2/2018 – ABIOMED had its price target raised by analysts at Morgan Stanley from $204.00 to $259.00. They now have an “equal weight” rating on the stock.
  • 2/2/2018 – ABIOMED had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $280.00 price target on the stock.
  • 2/1/2018 – ABIOMED had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $300.00 price target on the stock.
  • 2/1/2018 – ABIOMED had its “positive” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $300.00 price target on the stock, up previously from $220.00.
  • 1/20/2018 – ABIOMED was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 1/19/2018 – ABIOMED had its price target raised by analysts at Leerink Swann from $200.00 to $265.00. They now have an “outperform” rating on the stock.
  • 1/12/2018 – ABIOMED had its price target raised by analysts at Jefferies Group LLC to $250.00. They now have a “buy” rating on the stock.
  • 1/11/2018 – ABIOMED was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/4/2018 – ABIOMED had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 12/29/2017 – ABIOMED was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $213.00 price target on the stock. According to Zacks, “Over the last six months, Abiomed has been trading above the broader industry. Management expects that robust demand for the Impella product line will continue to drive Abiomed’s top line. The company’s expanding product portfolio will improve penetration into both the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that both Impella 2.5 and CP continue to add centers in the U.S. The company also announced the successful launch of the Abiomed Impella Quality Program in fiscal 2017 to improve clinical outcomes. Also, cost-savings efforts remain encouraging. However, intensifying competition in the niche markets is likely to mar prospects over the long haul. Abiomed’s significant international presence exposes it to fluctuations in currency exchange rates. We believe Abiomed will face increasing pricing pressure due to growing competition in its key markets.”
  • 12/21/2017 – ABIOMED had its price target raised by analysts at Jefferies Group LLC from $208.00 to $220.00. They now have a “buy” rating on the stock.

Shares of ABIOMED, Inc. (ABMD) opened at $229.38 on Monday. The firm has a market cap of $10,156.45, a P/E ratio of 115.85, a PEG ratio of 3.04 and a beta of 0.36. ABIOMED, Inc. has a 1-year low of $107.33 and a 1-year high of $255.42.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.20. The firm had revenue of $154.00 million during the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The business’s quarterly revenue was up 34.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS. equities analysts forecast that ABIOMED, Inc. will post 2.39 EPS for the current year.

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Receive News & Ratings for ABIOMED Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply